Skip to main content

Table 2 38G model performance compared to CAPRA-S for association with BCR in the training cohort (n = 100)

From: A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence

  Sensitivity Specificity PPV NPV
Overall BCR
38G 94.44 92.31 92.73 94.12
CAPRA-S 37.74 94 86.96 58.75
BCR within 1.5 years
38G 100 62.65 42.59 100
CAPRA-S 52.17 86.25 52.17 86.25
BCR within 3 years
38G 95.35 79.37 75.93 96.15
CAPRA-S 41.86 91.67 78.26 68.75
BCR within 5 years
38G 94.12 89.09 88.89 94.23
CAPRA-S 40 94.34 86.96 62.5
BCR within 7 years
38G 92.31 88.89 88.89 92.31
CAPRA-S 39.22 94.23 86.96 61.25